Eteplirsen

DB06014ApprovedInvestigationalGene TherapiesAntisense Oligonucleotides

Eteplirsen is an antisense oligonucleotide used to treat Duchenne muscular dystrophy (DMD) in patients with a confirmed mutation of the DMD gene that is amenable to exon 51 skipping. Eteplirsen is a synthetic antisense oligonucleotide and a phosphorodiamidate morpholino oligomer.

Protein structure of Eteplirsen
Mechanism
Curator reviewed · 7 references
Primary indication
Eteplirsen is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients who have a confirmed mutation of the DMD gene that is amenable to exon 51 skipping.Curator reviewed · 1 structured indication
First approval
United States, 2016
Code names
AVI-4658
Brand names
  • Exondys

Resolves to

What you can answer from here — as of February 01, 2022

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
6Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1Structured indicationCondition, population, route and combination as fields, not prose
Sign in
2Marketed productsAcross 1 country and 1 labeller
Sign in
1ATC codeIncluding every combination product, plus 14 drug categories
Sign in
6+ReferencesStructured and connected to the statements they support
Sign in

Which other approved drugs treat the same conditions as Eteplirsen, and which companies have late-stage candidates in those indications?

Create a free account or log in to explore the full data card.

Create Account